Barclays PLC Outlook Therapeutics, Inc. Transaction History

Barclays PLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 15, 2024	BUY	$0.22 - $0.66 $41,569 - $124,708	188,952 Added 701.09%	215,903 $85,000
Q3 2023 Nov 07, 2023	SELL	$0.2 - $1.78 $802 - $7,141	-4,012 Reduced 12.96%	26,951 $6,000
Q2 2023 Aug 03, 2023	SELL	$1.02 - $1.89 $49,191 - $91,149	-48,227 Reduced 60.9%	30,963 $54,000
Q1 2023 May 04, 2023	BUY	$1.0 - $1.35 $47,384 - $63,968	47,384 Added 148.98%	79,190 $86,000
Q4 2022 Feb 13, 2023	BUY	$0.87 - $1.33 $23,302 - $35,622	26,784 Added 533.33%	31,806 $34,000
Q3 2022 Nov 03, 2022	SELL	$1.02 - $1.26 $941 - $1,162	-923 Reduced 15.53%	5,022 $6,000
Q2 2022 Aug 12, 2022	SELL	$0.91 - $2.01 $11,419 - $25,223	-12,549 Reduced 67.85%	5,945 $6,000
Q1 2022 May 16, 2022	SELL	$1.22 - $2.03 $109,321 - $181,904	-89,608 Reduced 82.89%	18,494 $32,000
Q4 2021 Feb 14, 2022	BUY	$1.27 - $2.23 $91,066 - $159,904	71,706 Added 197.02%	108,102 $147,000
Q3 2021 Nov 09, 2021	BUY	$2.12 - $2.76 $41,075 - $53,474	19,375 Added 113.83%	36,396 $79,000
Q2 2021 Aug 13, 2021	BUY	$1.78 - $2.76 $13,608 - $21,100	7,645 Added 81.54%	17,021 $42,000
Q1 2021 May 13, 2021	BUY	$0.94 - $3.31 $8,813 - $31,034	9,376 New	9,376 $21,000
Q2 2020 Aug 12, 2020	SELL	$0.56 - $1.41 $19,726 - $49,668	-35,226 Closed	0 $0
Q4 2019 Feb 10, 2020	BUY	$0.53 - $1.59 $18,669 - $56,009	35,226 New	35,226 $21,000
Q2 2019 Aug 14, 2019	SELL	$0.91 - $7.68 $17 - $145	-19 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$4.26 - $10.56 $80 - $200	19 New	19 $0

31.5K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.17B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.